Chest
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only ArticlesPatient Values and Preferences in Decision Making for Antithrombotic Therapy: A Systematic Review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Section snippets
Eligibility Criteria
We included studies that enrolled individuals potentially at risk of or having direct experience with conditions for which antithrombotic therapy may be indicated. We specifically included:
- •
Studies that examined patient preferences for antithrombotic therapy vs no or alternative antithrombotic therapy, which includes receiving both treatment for thromboembolic disease and prophylaxis as defined previously
- •
Studies that examined in the context of consideration of antithrombotic therapy how
Included Studies
Of 48 studies selected for inclusion, 16 focused on patients with atrial fibrillation,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 five on patients with VTE,19, 20, 21, 22, 23 four on stroke or myocardial infarction prophylaxis,24, 25, 26, 27 six on thrombolysis in acute stroke or myocardial infarction,28, 29, 30, 31, 32, 33 and 17 on the burden of antithrombotic treatment.34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 Strategies used to elicit patient preferences
Summary of Findings
Three studies reported compelling findings of a higher disutility associated with stroke than with bleed. Alonso-Coello et al3 found that 19 of 96 participants (20%) were willing to accept > 35 additional bleeds on warfarin for 3% absolute risk reduction of stroke. For this 20%, the disutility associated with one stroke was equal to the disutility associated with 11.6 bleeding episodes. The median threshold that patient-participants were willing to accept was 10 bleeds for a 3% reduction in
Summary of Findings
These studies illustrate significant variability in elicited patient values and preferences regarding thrombosis prophylaxis and treatment. Locadia et al20 described extremely large between-patient variability with regard to participant willingness to accept warfarin treatment at varying thresholds of recurrent DVT. In another study by Locadia et al,21 the authors concluded that preferences stated in the form of health state utilities varied significantly across the three methods (Table 3).
Summary of Findings
A study by O'Meara et al23 found that no participant values and preferences were consistent with taking streptokinase, which differs from the findings of Lenert and Soetikno22 where the majority of participant preferences were consistent with use of streptokinase. Lenert and Soetikno22 explained these differences in results by arguing that their participants were better educated about the risks and benefits of DVT and its treatment, given that participants were presented with video and audio
Summary of Findings
The results of each of these studies illustrate how design features and participant characteristics may affect reported values and preferences. For example, in the 2001 study by Man-Son-Hing et al,26 enrollees in the Aspirin for Primary Prevention in the Low-risk Elderly (APPLE) pilot study would accept aspirin to gain a significantly smaller reduction in first-time stroke risk compared with those who did not enroll. This finding may indicate that individuals who enroll in trials may have
Summary of Findings
Results from Slot and Berge30 indicate that compared with individuals who have not experienced a given health event, those who have may associate a higher utility to that event. This factor may be important to consider when eliciting health state valuations for outcomes associated with antithrombotic treatment. These studies also illustrate that other factors such as age, sex, and living situation affect willingness to accept or reject treatment options (Table 6).
Summary of Findings
One could infer from the results of Heyland et al31 that many patients are extremely stroke averse (valuing avoiding stroke to a considerably greater extent than avoiding death). More likely, the results suggest that patients place a higher value on avoiding treatment-induced adverse (eg, hemorrhagic stroke) events than avoiding events prevented as a result of treatment. This latter interpretation is consistent with results from Fuller et al,5 who examined the relative aversion to thrombotic
Summary of Findings
Warfarin is, for most patients, associated with relatively limited impact on quality of life and the ability to carry out daily activities. Although some patients report anxiety or worry over the risks that they incur while taking warfarin therapy,35, 36, 37, 40, 41 they generally are satisfied with this treatment.39, 46 Other elements of burden that patients report include dietary modifications and the inconvenience associated with frequent blood monitoring. Duration of warfarin therapy was
Biases and Limitations Associated With Included Studies
There are a number of limitations associated with the included studies. Only three studies reported comprehension screening of potential participants,3, 4, 12 and two used only the data from participants with consistent results.6, 31 Le Sage and colleagues48 had research assistants walk through the survey with participants to ensure that the participants understood all the questions. It is possible that for those studies that did not pretest for comprehension, preferences elicited using methods
Discussion
We have carried out a systematic review of studies reporting patient values and preferences with regard to antithrombotic treatment. The results obtained through this review provide direction for guideline developers to base recommendations on patient values. In particular, this review highlights the apparently large variability in participant health state valuations and the factors, other than the impact of alternative management strategies on quantity and quality of life, that influence
Acknowledgments
Author contributions: As Topic Editor, Ms MacLean oversaw the development of this article, including the data analysis and findings contained herein.
Ms MacLean: served as Topic Editor.
Mr Mulla: served as a panelist.
Dr Jankowski: served as a panelist.
Dr Akl: served as a panelist.
Dr Vandvik: served as a panelist.
Mr Ebrahim: served as a panelist.
Ms McLeod: served as a panelist.
Ms Bhatnagar: served as a panelist.
Dr Guyatt: served as a panelist.
Financial/nonfinancial disclosures: In summary, the
References (57)
- et al.
Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation
Lancet
(2000) - et al.
Thrombolytic treatment for stroke: patient preferences for treatment, information, and involvement
J Stroke Cerebrovasc Dis
(2009) - et al.
Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective
J Clin Epidemiol
(2000) - et al.
Determinants of compliance with anticoagulation: A case-control study
Am J Med
(1997) - et al.
Preference and compliance in postoperative thromboembolism prophylaxis among gynecologic oncology patients
Obstet Gynecol
(2002) - et al.
Knowledge of venous thromboembolism (VTE) prevention among hospitalized patients
J Vasc Nurs
(2008) - et al.
Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement
Health Res Policy Syst
(2006) - et al.
Advanced topics in moving from evidence to action: decision making and the patient. Chapter 22.2
- et al.
Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study
BMC Health Serv Res
(2008)
Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study
BMJ
Avoidance hierarchies and preferences for anticoagulation—semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarin
Age Ageing
Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation
JAMA
The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life
Arch Intern Med
Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation
Stroke
Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation
BMJ
Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial
CMAJ
A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial
JAMA
The effect of qualitative vs. quantitative presentation of probability estimates on patient decision-making: a randomized trial
Health Expect
The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis
BMJ
A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences
Br J Gen Pract
A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial
Qual Saf Health Care
Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery
Am J Cardiovasc Drugs
Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences
Thromb Haemost
A comparison of 3 valuation methods for temporary health states in patients treated with oral anticoagulants
Med Decis Making
Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis
J Am Med Inform Assoc
A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis
N Engl J Med
Cited by (229)
A novel framework for incorporating patient values and preferences in making guideline recommendations: guideline panel surveys
2023, Journal of Clinical EpidemiologyQualitative study of guideline panelists: innovative surveys provided valuable insights regarding patient values and preferences
2023, Journal of Clinical EpidemiologyGRADE summary of findings tables enhanced understanding of values and preferences evidence
2022, Journal of Clinical EpidemiologyGRADE guidelines 20: Assessing the certainty of evidence in the importance of outcomes or values and preferences – inconsistency, imprecision, and other domains
2021, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen
Funding/Support: The Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines received support from the National Heart, Lung, and Blood Institute [R13 HL104758] and Bayer Schering Pharma AG. Support in the form of educational grants was also provided by Bristol-Myers Squibb; Pfizer, Inc; Canyon Pharmaceuticals; and sanofi-aventis US.
Disclaimer: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at http://chestjournal.chestpubs.org/content/141/2_suppl/1S.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
- 1
Ms MacLean is currently at the University of British Columbia, Faculty of Medicine, School of Population of Public Health.